Online inquiry

IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1411MR)

This product GTTS-WQ1411MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_024690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94025
UniProt ID Q8WXI7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1411MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9701MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ12778MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ13568MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ14436MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ10142MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ66MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ13211MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ890MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW